[go: up one dir, main page]

GB9903035D0 - Treating cancer - Google Patents

Treating cancer

Info

Publication number
GB9903035D0
GB9903035D0 GBGB9903035.5A GB9903035A GB9903035D0 GB 9903035 D0 GB9903035 D0 GB 9903035D0 GB 9903035 A GB9903035 A GB 9903035A GB 9903035 D0 GB9903035 D0 GB 9903035D0
Authority
GB
United Kingdom
Prior art keywords
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB9903035.5A
Other versions
GB2335739A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Liverpool
Original Assignee
University of Liverpool
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9803446A external-priority patent/GB2334577A/en
Application filed by University of Liverpool filed Critical University of Liverpool
Priority to GB9903035A priority Critical patent/GB2335739A/en
Priority to JP2000532728A priority patent/JP2002504354A/en
Priority to PCT/GB1999/000502 priority patent/WO1999042090A2/en
Priority to AU25385/99A priority patent/AU753588B2/en
Priority to PCT/GB1999/000505 priority patent/WO1999042836A1/en
Priority to CA002321458A priority patent/CA2321458A1/en
Priority to AT99905087T priority patent/ATE238557T1/en
Priority to AT99905083T priority patent/ATE238554T1/en
Priority to PCT/GB1999/000506 priority patent/WO1999042821A2/en
Priority to AT99905086T priority patent/ATE238556T1/en
Priority to PCT/GB1999/000512 priority patent/WO1999042839A2/en
Priority to AU26300/99A priority patent/AU749180B2/en
Priority to PCT/GB1999/000509 priority patent/WO1999042837A1/en
Priority to EP99905087A priority patent/EP1057032B1/en
Priority to DE69907156T priority patent/DE69907156T2/en
Priority to DE69907151T priority patent/DE69907151D1/en
Priority to EP99905086A priority patent/EP1057031B1/en
Priority to EP99905083A priority patent/EP1057029B1/en
Priority to EP99906326A priority patent/EP1057033B1/en
Priority to DE69907155T priority patent/DE69907155T2/en
Priority to AT99906326T priority patent/ATE238558T1/en
Priority to US09/622,577 priority patent/US6878526B1/en
Priority to AT99905084T priority patent/ATE238555T1/en
Priority to DE69907152T priority patent/DE69907152D1/en
Priority to CA002321467A priority patent/CA2321467A1/en
Priority to AU25380/99A priority patent/AU739001B2/en
Priority to PCT/GB1999/000501 priority patent/WO1999042835A1/en
Priority to JP2000532719A priority patent/JP2002504353A/en
Priority to JP2000532727A priority patent/JP2002504688A/en
Priority to DE69907154T priority patent/DE69907154T2/en
Priority to JP2000532725A priority patent/JP2002504687A/en
Priority to EP99905082A priority patent/EP1057028B1/en
Priority to AU25382/99A priority patent/AU741712B2/en
Priority to CA002321438A priority patent/CA2321438A1/en
Priority to AT99905082T priority patent/ATE238553T1/en
Priority to PCT/GB1999/000500 priority patent/WO1999042834A2/en
Priority to JP2000532726A priority patent/JP2002504496A/en
Priority to EP99905081A priority patent/EP1057027A2/en
Priority to CA002321479A priority patent/CA2321479A1/en
Priority to CA002321481A priority patent/CA2321481A1/en
Priority to CA002321480A priority patent/CA2321480A1/en
Priority to DE69907153T priority patent/DE69907153T2/en
Priority to US09/622,277 priority patent/US6521407B1/en
Priority to AU26301/99A priority patent/AU2630199A/en
Priority to AU25379/99A priority patent/AU743454B2/en
Priority to AU25381/99A priority patent/AU735896B2/en
Priority to JP2000532107A priority patent/JP2002503822A/en
Priority to AU25384/99A priority patent/AU741632B2/en
Priority to CA002321482A priority patent/CA2321482A1/en
Priority to PCT/GB1999/000503 priority patent/WO1999042828A2/en
Priority to EP99905084A priority patent/EP1057030B1/en
Priority to JP2000532712A priority patent/JP2002504683A/en
Publication of GB9903035D0 publication Critical patent/GB9903035D0/en
Publication of GB2335739A publication Critical patent/GB2335739A/en
Priority to US10/321,555 priority patent/US20030134315A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GB9903035A 1998-02-18 1999-02-10 Screening anti-cancer agents Withdrawn GB2335739A (en)

Priority Applications (53)

Application Number Priority Date Filing Date Title
GB9903035A GB2335739A (en) 1998-02-18 1999-02-10 Screening anti-cancer agents
JP2000532728A JP2002504354A (en) 1998-02-18 1999-02-18 Cancer Treatment
PCT/GB1999/000502 WO1999042090A2 (en) 1998-02-18 1999-02-18 Treating cancer
AU25385/99A AU753588B2 (en) 1998-02-18 1999-02-18 Treating cancer
PCT/GB1999/000505 WO1999042836A1 (en) 1998-02-18 1999-02-18 Treating cancer
CA002321458A CA2321458A1 (en) 1998-02-18 1999-02-18 Treating cancer
AT99905087T ATE238557T1 (en) 1998-02-18 1999-02-18 CANCER TREATMENT
AT99905083T ATE238554T1 (en) 1998-02-18 1999-02-18 CANCER TREATMENT
PCT/GB1999/000506 WO1999042821A2 (en) 1998-02-18 1999-02-18 Treating cancer
AT99905086T ATE238556T1 (en) 1998-02-18 1999-02-18 CANCER TREATMENT
PCT/GB1999/000512 WO1999042839A2 (en) 1998-02-18 1999-02-18 Treating cancer
AU26300/99A AU749180B2 (en) 1998-02-18 1999-02-18 Treating cancer
PCT/GB1999/000509 WO1999042837A1 (en) 1998-02-18 1999-02-18 Treating cancer
EP99905087A EP1057032B1 (en) 1998-02-18 1999-02-18 Treating cancer
DE69907156T DE69907156T2 (en) 1998-02-18 1999-02-18 CANCER TREATMENT
DE69907151T DE69907151D1 (en) 1998-02-18 1999-02-18 CANCER TREATMENT
EP99905086A EP1057031B1 (en) 1998-02-18 1999-02-18 Treating cancer
EP99905083A EP1057029B1 (en) 1998-02-18 1999-02-18 Treating cancer
EP99906326A EP1057033B1 (en) 1998-02-18 1999-02-18 Treating cancer
DE69907155T DE69907155T2 (en) 1998-02-18 1999-02-18 CANCER TREATMENT
AT99906326T ATE238558T1 (en) 1998-02-18 1999-02-18 CANCER TREATMENT
US09/622,577 US6878526B1 (en) 1998-02-18 1999-02-18 Treating cancer
AT99905084T ATE238555T1 (en) 1998-02-18 1999-02-18 CANCER TREATMENT
DE69907152T DE69907152D1 (en) 1998-02-18 1999-02-18 CANCER TREATMENT
CA002321467A CA2321467A1 (en) 1998-02-18 1999-02-18 Treating cancer
AU25380/99A AU739001B2 (en) 1998-02-18 1999-02-18 Treating cancer
PCT/GB1999/000501 WO1999042835A1 (en) 1998-02-18 1999-02-18 Treating cancer
JP2000532719A JP2002504353A (en) 1998-02-18 1999-02-18 Cancer Treatment
JP2000532727A JP2002504688A (en) 1998-02-18 1999-02-18 Cancer Treatment
DE69907154T DE69907154T2 (en) 1998-02-18 1999-02-18 CANCER TREATMENT
JP2000532725A JP2002504687A (en) 1998-02-18 1999-02-18 Cancer Treatment
EP99905082A EP1057028B1 (en) 1998-02-18 1999-02-18 Treating cancer
AU25382/99A AU741712B2 (en) 1998-02-18 1999-02-18 Treating cancer
CA002321438A CA2321438A1 (en) 1998-02-18 1999-02-18 Treating cancer
AT99905082T ATE238553T1 (en) 1998-02-18 1999-02-18 CANCER TREATMENT
PCT/GB1999/000500 WO1999042834A2 (en) 1998-02-18 1999-02-18 Treating cancer
JP2000532726A JP2002504496A (en) 1998-02-18 1999-02-18 Cancer Treatment
EP99905081A EP1057027A2 (en) 1998-02-18 1999-02-18 Treating cancer
CA002321479A CA2321479A1 (en) 1998-02-18 1999-02-18 Treating cancer
CA002321481A CA2321481A1 (en) 1998-02-18 1999-02-18 Treating cancer
CA002321480A CA2321480A1 (en) 1998-02-18 1999-02-18 Treating cancer
DE69907153T DE69907153T2 (en) 1998-02-18 1999-02-18 CANCER TREATMENT
US09/622,277 US6521407B1 (en) 1998-02-18 1999-02-18 Methods for determining chemosensitivity of cancer cells based upon expression of negative and positive signal transduction factors
AU26301/99A AU2630199A (en) 1998-02-18 1999-02-18 Treating cancer
AU25379/99A AU743454B2 (en) 1998-02-18 1999-02-18 Treating cancer
AU25381/99A AU735896B2 (en) 1998-02-18 1999-02-18 Treating cancer
JP2000532107A JP2002503822A (en) 1998-02-18 1999-02-18 Cancer Treatment
AU25384/99A AU741632B2 (en) 1998-02-18 1999-02-18 Treating cancer
CA002321482A CA2321482A1 (en) 1998-02-18 1999-02-18 Treating cancer
PCT/GB1999/000503 WO1999042828A2 (en) 1998-02-18 1999-02-18 Treating cancer
EP99905084A EP1057030B1 (en) 1998-02-18 1999-02-18 Treating cancer
JP2000532712A JP2002504683A (en) 1998-02-18 1999-02-18 Cancer Treatment
US10/321,555 US20030134315A1 (en) 1998-02-18 2002-12-18 Treating cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9803446A GB2334577A (en) 1998-02-18 1998-02-18 Resistance of p53 mutant cancer cells to cytoxic effects of (chemo)therapeutic agents involving assay of cyclin D1 protein
GB9903035A GB2335739A (en) 1998-02-18 1999-02-10 Screening anti-cancer agents

Publications (2)

Publication Number Publication Date
GB9903035D0 true GB9903035D0 (en) 1999-03-31
GB2335739A GB2335739A (en) 1999-09-29

Family

ID=26313147

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9903035A Withdrawn GB2335739A (en) 1998-02-18 1999-02-10 Screening anti-cancer agents

Country Status (1)

Country Link
GB (1) GB2335739A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050136177A1 (en) * 2003-08-25 2005-06-23 Anthony Hesse Method for coloring landscaping materials using foamable dry colorant
US8021831B2 (en) 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004316A1 (en) * 1995-07-20 1997-02-06 Paracelsian, Inc. Determination of the presence of abnormal cellular proliferation through the detection of one or more cyclin dependent kinases

Also Published As

Publication number Publication date
GB2335739A (en) 1999-09-29

Similar Documents

Publication Publication Date Title
HUP0104857A3 (en) New cancer treatments
SI1176964T1 (en) Uses of et743 for treating cancer
GB9800942D0 (en) Well treatment
GB9805877D0 (en) Cancer
GB9816556D0 (en) Therapy
GB9703633D0 (en) Cancer therapy
GB9804361D0 (en) Cancer treatment
GB9819999D0 (en) Treatment of cancer
EP1018560A4 (en) Vectors for treating cancer
GB9903035D0 (en) Treating cancer
GB9827102D0 (en) New cancer treatments
GB2334579B (en) Treating cancer
GB9812151D0 (en) Treating cancer
GB9818524D0 (en) Inorgasmia treatment
GB9815497D0 (en) Treatment
GB9820000D0 (en) Cancer treatment
GB9818023D0 (en) Cancer treatment
AU4598100A (en) Treating cancer
GB9911302D0 (en) Treating cancer
GB0007254D0 (en) Treating cancer
GB9828550D0 (en) Treatment
GB2335437B (en) Treating hide
HK1033177A (en) Treating cancer
HK1033175A (en) Treating cancer
HK1033174A (en) Treating cancer

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)